Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Legend Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Legend Biotech's regulatory disclosures and financial reporting.
Legend Biotech (LEGN) reported preliminary CARVYKTI sales of approximately $524 million in net trade sales for the quarter ended September 30, 2025. The figure was provided by collaboration partner Janssen under their existing agreement.
Legend Biotech noted it has not independently verified this sales number. The final determination of revenue and gross profit for this period will be made upon completion of its financial statements, and the company’s independent auditors have not audited or reviewed the data. The filing also includes forward‑looking statements language regarding expectations for CARVYKTI sales and profitability.
Legend Biotech Corporation, through its wholly owned subsidiary Legend Biotech USA Inc., has entered into a new Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc. covering the manufacture and supply of ciltacabtagene autoleucel (cilta‑cel) for clinical and commercial use worldwide, excluding Greater China. The product will be manufactured at the existing GMP facility in Raritan, New Jersey that both parties already use, and this agreement replaces a prior interim supply arrangement signed in 2022.
The agreement will take effect after agreed transition steps are completed, including several quality and services agreements and any required health authority approvals, and it will end automatically if the broader collaboration and license agreement between the parties expires or is terminated. Janssen will pay Legend a transfer price for the product based on total production costs plus a markup, while the ultimate commercial and clinical supply costs will be shared equally under the existing collaboration framework. Janssen will also provide key raw materials to Legend at its own cost plus a markup, under customary commercial, quality, intellectual property, and indemnification terms.
Form 144 notice for Legend Biotech Corp (LEGN) reports a proposed sale of 1,000 American Depositary Shares through Fidelity Brokerage Services with an aggregate market value of $33,285 and an approximate sale date of 09/26/2025 on NASDAQ. The shares were acquired on 06/20/2022 as restricted stock vesting from the issuer and were paid as compensation. The filing lists 367,298,315 shares outstanding for the class and discloses a prior sale by Patrick Casey of 1,000 ADS on 06/26/2025 for $33,234. The filer signs the required representation that they are unaware of material nonpublic information.
Legend Biotech (LEGN) Form 144 disclosure: The filing notifies a proposed sale of 1,370 American Depositary Shares (ADS) valued at $45,210 to be sold via Fidelity Brokerage Services on NASDAQ on 09/24/2025. The shares were acquired 09/20/2025 through restricted stock vesting and were received as compensation. The filing also reports four prior ADS sales by the same person (Ying Huang) during the past three months totaling 40,577 ADS with gross proceeds of $1,566,086.36.
Legend Biotech Corp (LEGN) reported a Form 144 notice showing proposed sale of 1,357 American Depositary Shares through Fidelity Brokerage, listed on NASDAQ, with an aggregate market value of $46,111.81 and approximately 367,298,315 shares outstanding. The shares were acquired on 09/19/2025 through restricted stock vesting as compensation and the planned sale date is 09/23/2025. The filer also reported three prior ADS sales in June–July 2025 totaling 38,220 shares for gross proceeds of $1,505,975.55. The filing represents a routine insider sale report under Rule 144.
Legend Biotech Corp (LEGN) Form 144 summary: An insider plans to sell 474 American Depositary Shares on 09/23/2025 through Fidelity Brokerage Services. The shares were acquired on 09/19/2025 by Restricted Stock Vesting and were paid as compensation. The aggregate market value of the proposed sale is listed as $16,106.85, with the issuer's outstanding shares shown as 367,298,315. The filing also discloses a prior sale by the same person: 642 ADS sold on 07/23/2025 for $28,890.00. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Form 144 notice for Legend Biotech Corp (LEGN) reports a proposed sale of 307 American Depositary Shares (ADSs) with an aggregate market value of $10,438 and approximately 367,298,315 ADSs outstanding. The securities were acquired on 09/20/2025 through restricted stock vesting from the issuer and the stated nature of payment is compensation. The approximate date of sale listed is 09/23/2025. The filer also disclosed a prior sale on 06/24/2025 of 307 ADSs by Corazon D. Sanders for gross proceeds of $10,551.59. Several standard filing fields (issuer name, filer CIK/CCC, and contact details) appear blank in the provided content.
Legend Biotech disclosed termination and severance terms for Mr. Santos in an employment agreement. If termination triggers the shorter package, Mr. Santos would receive 12 months of base salary, the prior-year bonus if unpaid, a pro-rated portion of the target bonus for the termination year, COBRA reimbursements for up to 12 months, acceleration of any equity awards that would vest within the following 12 months (subject to any corporate performance goals), and a post-termination option exercise window extended to 12 months.
Under an enhanced package, Mr. Santos would receive 18 months of base salary, the prior-year bonus if unpaid, the full target bonus for the year of termination, COBRA reimbursements for up to 18 months, immediate full acceleration of all unvested equity awards without regard to performance, and an extended option exercise period of 18 months.
Legend Biotech reported total revenue of $255.1 million for the three months ended June 30, 2025 and $450.1 million for the six months, driven primarily by collaboration revenue (CARVYKTI) which rose to $219.7 million in Q2 and $405.3 million for H1. License revenue fell year-over-year due to timing of Janssen milestones, with license revenue of $35.3 million in Q2 versus $90.8 million a year earlier.
The company recorded a wider net loss of $125.4 million in Q2 and $226.3 million for H1; the MD&A attributes a large portion of the deterioration to unrealized foreign exchange losses (other expense of $108.1 million in Q2, $162.6 million in H1). Liquidity remains substantial with $266.6 million cash and $701.0 million time deposits (~$1.0 billion total). Management also reports CARVYKTI net trade sales of approximately $439 million and over 7,500 patients treated. Adjusted net income (non-IFRS) was $10.1 million in Q2 (ANI per share $0.03), illustrating the impact of excluding unrealized FX and certain non-cash items.